News Preview
Emideltide Keeps Getting a ‘No’ for Compounding. What’s the Problem?
The government has renewed its interest in peptides for drug development, but Emideltide, a promising peptide, is being excluded. Experts suggest that the compound's potential side effects and lack of clinical data may be the reasons behind this decision.
Want to stay up to date with the world events at sea or at home?
Explore Navvyx News - the best News app for seafarers.